onabotulinum toxin injection at least once between January 2011 and August 2018 at a single academic institution. All women were identified by CPT codes. Demographic and clinical variables were abstracted and women who underwent repeat treatment were identified. Procedural-related variables, such as dose, complications, and timing, were collected for each treatment. Cox proportional hazards models were used to estimate the association (hazard ratio and 95% confidence interval) between potential risk factors for timing of retreatment. Time to retreatment was defined as the time from first treatment to subsequent treatment or last contact with the health care system where no retreatment was noted. Median time to retreatment was estimated by methods of Kaplan & Meier. Exact binomial confidence intervals are used to describe variability of proportion in our cohort. Factors considered included: age, race, body mass index (BMI), menopausal status, diagnosis of neurogenic bladder, incontinence severity (demonstrated by pads used per day), urodynamic parameters, and units injected. RESULTS: Between January 2011 and August 2018, 154 women were treated with intradetrusor onabotulinum toxin; most (63%, n¼97) received more than one treatment. At the time of first treatment, women were 54 years old on average (range 21-86) with 48% noted as menopausal, 24% pre-menopausal, and the remainder unknown. A majority of the cohort was white non-Hispanic (78%), while the remainder was black/African American non-Hispanic (15.6%), and other race and ethnicities (6.5%). Most women never used tobacco (60%). Of the women with incontinence (n¼125), the majority had the diagnosis of mixed urinary incontinence (59%). Most women had not received any prior anti-incontinence procedure (73%). Overall, the median time to retreatment was 0. . CONCLUSION: Our findings are consistent with previous reports regarding the median time to re-treatment after initial intradetrusor botulinum toxin injection. It is difficult to predict timing of retreatment with onabotulinum toxin and there is no strong evidence to suggest any potential factors impact this timing. While we were limited by the relatively modest size of our study cohort, none of the identified factors indicated a shorter time to re-treatment.
OBJECTIVES: To review uterine pathology of patients undergoing laparoscopic supracervical hysterectomy with electromechanical (power) uterine morcellation and sacrocervicopexy for uterovaginal prolapse. MATERIALS AND METHODS: This retrospective cohort study used the electronic medical record to review the cases of 182 patients undergoing laparoscopic supracervical hysterectomy with uterine power morcellation and sacrocervicopexy performed by a single high-volume gynecologic surgeon at our institution between January 1, 2012 and December 31, 2017. Uterovaginal prolapse was the primary indication for surgery for all patients included. The electronic medical record was reviewed to determine demographic and operative variables, pathology reports, and any post-operative complications. RESULTS: Of the 182 patients undergoing this procedure, the mean age was 63.4 years (standard deviation: 9.73). 5.0% had a postoperative complication (3 with incisional cellulitis, 3 with trocar incision site herniation, 1 with urinary retention requiring an emergency department visit, 1 with severe constipation requiring disimpaction, and 1 with perforation of the cecum from a concurrent rectopexy performed by colorectal surgery requiring re-operation). No patient had a complication directly related to uterine power morcellation or uterine pathology. The median uterine mass was 55.5 grams (interquartile range: 38.8 -81.0). 49.9% of patients had leiomyomas noted in the pathology report, 40.7% had adenomyosis, 11.5% had uterine polyps, and 4.4% had endometrial hyperplasia (4 with simple hyperplasia without atypia, 1 with simple hyperplasia with focal atypia, 1 with complex hyperplasia without atypia, and 1 with complex hyperplasia with focal atypia). None of the patients with endometrial hyperplasia had reported abnormal uterine or postmenopausal bleeding and as such had not had endometrial sampling prior to surgery. 100% of patients had at least one follow up visit with the surgeon. CONCLUSION: While there has been extensive examination of the use of uterine power morcellation in benign minimally invasive hysterectomy, there is minimal data specifically focusing on its use for patients whose primary indication for hysterectomy is uterovaginal prolapse. While our sample is limited to a single institution, our data suggests that malignant pathology may be even rarer than that found in hysterectomy for other benign indications. These variations should be considered when making decisions about the use of uterine power morcellation.
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